Notizie Newsletter

11 Luglio 2019

Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer

To examine the association between postoperative chemotherapy and survival of women with stage IC mucinous ovarian cancer (MOC). Comprehensive nationwide tumor registry data from the Commission on Cancer-accredited facilities in the United States from 2004 to 2014 were retrospectively ...
Leggi tutto

11 Luglio 2019

10 luglio 2019 – È Guido Rasi il nuovo presidente della International Coalition of Medicines Regulatory Authorities

11 Luglio 2019

FDA Reviewing Isatuximab for Multiple Myeloma

July 10, 2019 - The FDA has accepted a Biologics License Application (BLA) for isatuximab for the treatment of patients with relapsed/refractory multiple myeloma, according to Sanofi, the manufacturer of the anti-CD38 monoclonal antibody. The BLA is based on the phase III ...
Leggi tutto

8 Luglio 2019

5 luglio 2019 – Conferma accertamento positivo – Ripiano della spesa farmaceutica per gli anni 2013-2017

8 Luglio 2019

5 luglio 2019 – Carenza Treosulfan (Tillomed) – modalità di richiesta d’importazione dall’estero

5 Luglio 2019

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Regorafenib confers an overall survival benefit in patients with refractory metastatic colorectal cancer; however, the adverse event profile of regorafenib has limited its use. Despite no supportive evidence, various dosing schedules are used clinically to alleviate toxicities. ...
Leggi tutto

5 Luglio 2019

FDA Approval Sought for Neratinib Combo in HER2+ Breast Cancer

July 1, 2019 - A supplemental new drug application (sNDA) has been submitted to the FDA for neratinib for use in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed at least 2 prior lines of HER2-directed ...
Leggi tutto

5 Luglio 2019

FDA Approves Avatrombopag in Chronic ITP

July 1, 2019 - The FDA has approved a supplemental new drug application (sNDA) to expand the use of avatrombopag to include the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to prior therapy. The approval of ...
Leggi tutto

5 Luglio 2019

Statement on steps to make health care professional and patient labeling information for prescription medications consistent and clear

July 1, 2019 - The FDA is committed to making sure that health care professionals and patients have up-to-date, accurate and actionable information about prescription medications so that informed treatment decisions can be made. We recognize that the choice of which medication ...
Leggi tutto

5 Luglio 2019

Cemiplimab Approved in Europe for Cutaneous Squamous Cell Carcinoma

July 1, 2019 - The European Commission approved cemiplimab for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation, according to Regeneron Pharmaceuticals ...
Leggi tutto

LAVORIAMO CON

News

LA PREVENZIONE DEL MELANOMA: AL VIA UNA CAMPAGNA NEI COOP.FI

TUMORI: “AIFA APPROVA LA FORMULAZIONE SOTTOCUTANEA E TRE NUOVE INDICAZIONI TERAPEUTICHE DI NIVOLUMAB”

TUMORE AL SENO: METASTASI SI DIFFONDONO COME GOCCE SU UNA SUPERFICIE. LA CAPACITÀ INVASIVA DIPENDE DALLA “FLUIDITÀ” DEL CANCRO

ONE HEALTH FOUNDATION: AL VIA IL PROGETTO IN 36 CENTRI ESTIVI IN ALBANIA. SULLA “NAVE DELLA SALUTE” SVOLTI PIU’ DI 550 TEST E VISITE MEDICHE

AL VIA LA TERZA EDIZIONE DELLA “NAVE DELLA SALUTE” ITALIA-ALBANIA. LA PREVENZIONE SALE A BORDO CON 17 MEDICI SPECIALISTI E 10 AMBULATORI

TOVORAFENIB È LA PRIMA TERAPIA MIRATA APPROVATA IN EUROPA NEL GLIOMA PEDIATRICO DI BASSO GRADO RECIDIVATO O REFRATTARIO, INDIPENDENTEMENTE DAL TIPO DI ALTERAZIONE DI BRAF

TOZORAKIMAB HA SODDISFATTO L’ENDPOINT PRIMARIO DELLO STUDIO DI FASE III MIRANDA NEI PAZIENTI CON BPCO

Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer

10 luglio 2019 – È Guido Rasi il nuovo presidente della International Coalition of Medicines Regulatory Authorities

FDA Reviewing Isatuximab for Multiple Myeloma

5 luglio 2019 – Conferma accertamento positivo – Ripiano della spesa farmaceutica per gli anni 2013-2017

5 luglio 2019 – Carenza Treosulfan (Tillomed) – modalità di richiesta d’importazione dall’estero

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

FDA Approval Sought for Neratinib Combo in HER2+ Breast Cancer

FDA Approves Avatrombopag in Chronic ITP

Statement on steps to make health care professional and patient labeling information for prescription medications consistent and clear

Cemiplimab Approved in Europe for Cutaneous Squamous Cell Carcinoma